↓ Skip to main content

Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine

Overview of attention for article published in Cochrane database of systematic reviews, October 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
twitter
5 X users

Citations

dimensions_citation
69 Dimensions

Readers on

mendeley
305 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Primaquine for preventing relapse in people with <i>Plasmodium vivax</i> malaria treated with chloroquine
Published in
Cochrane database of systematic reviews, October 2013
DOI 10.1002/14651858.cd004389.pub3
Pubmed ID
Authors

Gawrie NL Galappaththy, Prathap Tharyan, Richard Kirubakaran

Abstract

Plasmodium vivax infections are an important contributor to the malaria burden worldwide. The World Health Organization recommends a 14-day course of primaquine (0.25 mg/kg/day, giving an adult dose of 15 mg/day) to eradicate the liver stage of the parasite and prevent relapse of the disease. Many people find a 14-day primaquine regimen difficult to complete, and there is a potential risk of haemolytic anaemia in people with glucose-6-phosphate-dehydrogenase enzyme (G6PD) deficiency. This review evaluates primaquine in P. vivax, particularly alternatives to the standard 14-day course.

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 305 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Italy 1 <1%
Brazil 1 <1%
United Kingdom 1 <1%
Japan 1 <1%
Unknown 300 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 49 16%
Researcher 35 11%
Student > Bachelor 30 10%
Student > Ph. D. Student 29 10%
Student > Postgraduate 17 6%
Other 52 17%
Unknown 93 30%
Readers by discipline Count As %
Medicine and Dentistry 93 30%
Nursing and Health Professions 27 9%
Agricultural and Biological Sciences 18 6%
Social Sciences 17 6%
Pharmacology, Toxicology and Pharmaceutical Science 13 4%
Other 35 11%
Unknown 102 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2024.
All research outputs
#5,471,255
of 25,457,297 outputs
Outputs from Cochrane database of systematic reviews
#7,375
of 11,499 outputs
Outputs of similar age
#47,847
of 225,050 outputs
Outputs of similar age from Cochrane database of systematic reviews
#143
of 212 outputs
Altmetric has tracked 25,457,297 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,499 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 40.0. This one is in the 34th percentile – i.e., 34% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 225,050 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.